FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer

PURPOSE: While FGFR1 amplification has been described in breast cancer, the optimal treatment approach for FGFR1-amplified (FGFR1+) metastatic breast cancer (MBC) remains undefined. EXPERIMENTAL DESIGN: We evaluated clinical response to endocrine and targeted therapies in a cohort of patients with H...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Drago, Josh, Formisano, Luigi, Juric, Dejan, Niemierko, Andrzej, Servetto, Alberto, Wander, Seth, Spring, Laura, Vidula, Neelima, Peppercorn, Jeffrey, Younger, Jerry, Malvarosa, Giuliana, Yuen, Megan, Sgroi, Dennis, Isakoff, Steven J., Moy, Beverly, Ellisen, Leif W., Iafrate, John, Arteaga, Carlos L., Bardia, Aditya
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825550/
https://ncbi.nlm.nih.gov/pubmed/31371343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0138
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires